Department of Physical Medicine and Rehabilitation, University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
J Neurotrauma. 2013 Jun 1;30(11):938-45. doi: 10.1089/neu.2012.2578. Epub 2013 Jun 7.
Over the last decade, biomarker research has identified potential biomarkers for the diagnosis, prognosis, and management of traumatic brain injury (TBI). Several cerebrospinal fluid (CSF) and serum biomarkers have shown promise in predicting long-term outcome after severe TBI. Despite this increased focus on identifying biomarkers for outcome prognostication after a severe TBI, several challenges still exist in effectively modeling the significant heterogeneity observed in TBI-related pathology, as well as the biomarker-outcome relationships. Biomarker data collected over time are usually summarized into single-point estimates (e.g., average or peak biomarker levels), which are, in turn, used to examine the relationships between biomarker levels and outcomes. Further, many biomarker studies to date have focused on the prediction power of biomarkers without controlling for potential clinical and demographic confounders that have been previously shown to affect long-term outcome. In this article, we demonstrate the application of a practical approach to delineate and describe distinct subpopulations having similar longitudinal biomarker profiles and to model the relationships between these biomarker profiles and outcomes while taking into account potential confounding factors. As an example, we demonstrate a group-based modeling technique to identify temporal S100 calcium-binding protein B (S100b) profiles, measured from CSF over the first week post-injury, in a sample of adult subjects with TBI, and we use multivariate logistic regression to show that the prediction power of S100b biomarker profiles can be superior to the prediction power of single-point estimates.
在过去的十年中,生物标志物研究已经确定了用于创伤性脑损伤(TBI)诊断、预后和管理的潜在生物标志物。一些脑脊液(CSF)和血清生物标志物在预测严重 TBI 后的长期预后方面显示出了希望。尽管人们越来越关注识别严重 TBI 后预后生物标志物,但在有效模拟 TBI 相关病理学以及生物标志物-结果关系中观察到的显著异质性方面仍然存在一些挑战。随着时间的推移收集的生物标志物数据通常被汇总为单点估计值(例如,平均或峰值生物标志物水平),然后用于检查生物标志物水平与结果之间的关系。此外,迄今为止,许多生物标志物研究都集中在生物标志物的预测能力上,而没有控制以前显示会影响长期结果的潜在临床和人口统计学混杂因素。在本文中,我们展示了一种实用方法的应用,该方法用于描绘和描述具有相似纵向生物标志物特征的不同亚群,并在考虑潜在混杂因素的情况下建立这些生物标志物特征与结果之间的关系。例如,我们展示了一种基于群组的建模技术,用于识别在 TBI 成年受试者的 CSF 中测量的伤后第一周内的 S100 钙结合蛋白 B(S100b)时间特征,并使用多元逻辑回归表明 S100b 生物标志物特征的预测能力可以优于单点估计值的预测能力。